# An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

> **NCT04185363** · PHASE3 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Progressive Familial Intrahepatic Cholestasis (PFIC)

## Interventions

- **DRUG:** Maralixibat

## Key facts

- **NCT ID:** NCT04185363
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-08
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-04-23
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185363, "An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04185363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*